Reactions
17 reactions
folic acid+waterfolic acid+water
Transported by SLC19A1
Reaction pageReversibleBalancedEC 3.1.3.11GO:0005615, GO:0005829
Human-GEM MAR01047CC BY 4.0Reference data
folic acid+NADH(2-)7,8-dihydrofolate+NAD(+)
Reaction pageReversibleBalancedEC 1.5.1.3GO:0005829
Human-GEM MAR04654CC BY 4.0Reference data
folic acid+NADPH(4-)7,8-dihydrofolate+NADP(3-)
Reaction pageReversibleBalancedEC 1.5.1.3GO:0005829
Human-GEM MAR04655CC BY 4.0Reference data
folic acid+NADPH(4-)7,8-dihydrofolate+NADP(3-)
Reaction pageLeft to rightBalancedEC 1.5.1.3GO:0005759
Human-GEM MAR04656CC BY 4.0Reference data
Reaction pageLeft to rightBalancedGO:0005829, GO:0005759
Human-GEM MAR05006CC BY 4.0Reference data
Transported by FOLR1 or FOLR3 or FOLR2
Reaction pageLeft to rightBalancedGO:0005615, GO:0005829
Human-GEM MAR05007CC BY 4.0Reference data
folic acid+protonfolic acid+proton
Transported by SLC46A1
Reaction pageLeft to rightBalancedGO:0005615, GO:0005829
Human-GEM MAR06893CC BY 4.0Reference data
folic acid+waterfolic acid+water
Transported by SLC19A1
Reaction pageReversibleBalancedGO:0005829, GO:0005615
Human-GEM MAR07684CC BY 4.0Reference data
Reaction pageReversibleBalance undeterminableGO:0005615
Human-GEM MAR09146CC BY 4.0Reference data
ATP+folic acid+waterADP+folic acid+proton+phosphate(3-)
Transported by ABCC2 or ABCC1 or ABCC5 or ABCG2 or ABCC4
Reaction pageLeft to rightBalancedGO:0005829, GO:0005615
Human-GEM MAR09882CC BY 4.0Reference data
2-oxoglutarate(2-)+folic acid+sodium(1+)2-oxoglutarate(2-)+folic acid+sodium(1+)
Transported by SLC22A6
Reaction pageReversibleBalancedGO:0005829, GO:0005615
Human-GEM MAR09883CC BY 4.0Reference data
folic acid+sulfatefolic acid+sulfate
Transported by SLC22A7 or SLC22A8
Reaction pageReversibleBalancedGO:0005615, GO:0005829
Human-GEM MAR09884CC BY 4.0Reference data
Papers screened
771 papers
- Compound
- folic acid
- Screened
- 771
- Admitted
- 0
- Discarded
- 86
- Not read
- 685
- Showing
- 200 of 771
Discarded: another reason, stated per paper44 papers
- NCT00193219design×1 — allocation NA -- not randomised2026-09-29
- NCT00193414design×1 — allocation NA -- not randomised2026-09-29
- NCT00267865design×1 — allocation NA -- not randomised2026-09-29
- NCT00321685design×1 — allocation NA -- not randomised2026-09-29
- NCT00352755design×1 — allocation NA -- not randomised2026-09-29
- NCT00354978design×1 — allocation NON_RANDOMIZED -- not randomised2026-09-29
- NCT00392834design×1 — allocation NON_RANDOMIZED -- not randomised2026-09-29
- NCT00396812design×1 — allocation NA -- not randomised2026-09-29
- NCT00450801design×1 — allocation NA -- not randomised2026-09-29
- NCT00539617design×1 — allocation NA -- not randomised2026-09-29
- NCT00544414design×1 — allocation NA -- not randomised2026-09-29
- NCT00594815design×1 — allocation NA -- not randomised2026-09-29
and 32 more.
Discarded: the wrong intervention33 papers
- PMID:42082233no claim extracted — subject_is_the_outcome2026-09-29
- NCT00068692intervention×1 — no declared intervention names folic acid2026-09-29
- NCT00075725intervention×1 — no declared intervention names folic acid2026-09-29
- NCT00079274intervention×1 — no declared intervention names folic acid2026-09-29
- NCT00112918intervention×1 — no declared intervention names folic acid2026-09-29
- NCT00143403intervention×1 — no declared intervention names folic acid2026-09-29
- NCT00217737intervention×1 — no declared intervention names folic acid2026-09-29
- NCT00418938intervention×1 — no declared intervention names folic acid2026-09-29
- NCT00424294intervention×1 — no declared intervention names folic acid2026-09-29
- NCT00439517intervention×1 — no declared intervention names folic acid2026-09-29
- NCT00470158intervention×1 — no declared intervention names folic acid2026-09-29
- NCT00500292intervention×1 — no declared intervention names folic acid2026-09-29
and 21 more.
Discarded: no extractable result5 papers
- PMID:39920638claims extracted but the two passes did not agree2026-09-29
- NCT00606502declared_contrast×4 — no posted analysis compares a folic acid arm with a placebo/no-intervention arm and carries a p-value (Pralatrexate=EXPERIMENTAL+subject, Erlotinib=ACTIVE_COMPARATOR+subject)2026-09-29
- NCT00609518declared_contrast×4 — no posted analysis compares a folic acid arm with a placebo/no-intervention arm and carries a p-value (Standard Vitamin and Steroid Schedule + Pemetrexed=ACTIVE_COMPARATOR+subject, Simplified Vitamin and Steroid Schedule + Pemetrexed=EXPERIMENTAL+subject)2026-09-29
- NCT00932113declared_contrast×6, reporting_status×1 — no posted analysis compares a folic acid arm with a placebo/no-intervention arm and carries a p-value (Adalimumab=ACTIVE_COMPARATOR, Methotrexate (MTX)=ACTIVE_COMPARATOR+subject)2026-09-29
- NCT01356966declared_contrast×3 — no posted analysis compares a folic acid arm with a placebo/no-intervention arm and carries a p-value (Tetrahydrobiopterin + Folate=EXPERIMENTAL+subject, Placebo + Folate=PLACEBO_COMPARATOR+subject)2026-09-29
Discarded: an endpoint this vocabulary does not hold3 papers
- PMID:40552686no claim extracted — no_outcome_node — measured: neural tube defect prevalence per 10,000 births, modelled under folic acid fortification/supplementation strategies | neural tube defect prevalence per 10,000 births, decision-analysis model output2026-09-29
- PMID:41705996no claim extracted — no_outcome_node — measured: malaria parasite clearance at day 3 and antimalarial treatment failure at days 7/14/28, pooled risk ratio | malaria parasite clearance (day 3) and antimalarial treatment failure (days 7/14/28), pooled risk ratio2026-09-29
- PMID:42739064no claim extracted — no_outcome_node — measured: plasma unmetabolized folic acid (UMFA) concentration, meta-analysis of 5-MTHF-for-folic-acid substitution trials, SMD | plasma unmetabolized folic acid (UMFA) concentration, meta-analysis standardised mean difference2026-09-29
Discarded: no comparator1 paper
- PMID:40306386no claim extracted — comparator_not_absence2026-09-29
Not read yet685 papers
- PMID:106910642026-09-29
- PMID:147620352026-09-29
- PMID:158708212026-09-29
- PMID:165316142026-09-29
- PMID:100815202026-09-29
- PMID:104215912026-09-29
- PMID:104290192026-09-29
- PMID:104529052026-09-29
- PMID:105882162026-09-29
- PMID:105916692026-09-29
- PMID:105979552026-09-29
- PMID:105979562026-09-29
and 673 more.
Measured, not recorded
- Compound
- folic acid
- Endpoints measured
- 21 endpoints
- Recorded as a finding
- No
Show what was measured
Change in Pepsinogen I/II Ratio (PGR)
increases, pooled MD = 2.22 (95% CI 1.54-2.91)
Figure 9 showed that a significant difference was observed between the folic acid therapy group and the lack folic acid therapy group (pooled MD = 2.22, 95% CI: 1.54–2.91, p < 0.00001).
PMID:39920638 · one of two readings recorded this
Change in Pepsinogen I (PGI)
increases, MD = 27.20 (95% CI 23.84-30.56)
Figure 8 showed that a significant difference was observed in the change of PGI between the folic acid therapy group and the lack folic acid group (MD = 27.20, 95%CI:23.84–30.56, p < 0.00001).
PMID:39920638 · one of two readings recorded this
gastric function, Pepsinogen I (PGI) concentration change
increases, MD = 27.20, 95%CI:23.84-30.56, p < 0.00001
Not recorded as a finding: No outcome node in the supplied vocabulary corresponds to serum pepsinogen I or the PGI/PGII ratio; dropped for no_outcome_node within a paper that otherwise yielded a claim.
Figure 8 showed that a significant difference was observed in the change of PGI between the folic acid therapy group and the lack folic acid group (MD = 27.20, 95%CI:23.84–30.56, p < 0.00001).
PMID:39920638 · one of two readings recorded this
total effective rate (clinical effectiveness composite)
increases, 95.09% vs.79.06%, pooled RR = 1.19, 95% CI: 1.12-1.26
Figure 3 showed that a significant difference was observed in the total effective rate between the folic acid therapy group and the lack folic acid group (95.09% vs.79.06%, pooled RR = 1.19, 95% CI: 1.12–1.26, p < 0.00001).
PMID:39920638 · one of two readings recorded this
Total effective rate (clinical response)
increases, pooled RR = 1.19 (95% CI: 1.12-1.26), n = 1364
Figure 3 showed that a significant difference was observed in the total effective rate between the folic acid therapy group and the lack folic acid group (95.09% vs.79.06%, pooled RR = 1.19, 95% CI: 1.12–1.26, p < 0.00001).
PMID:39920638 · one of two readings recorded this
Total effective rate (clinical response), change in pepsinogen I and pepsinogen I/II ratio, and incidence of total adverse events, folic acid add-on therapy versus conventional therapy in H. pylori-associated chronic atrophic gastritis, pooled across 16 RCTs
increases, pooled RR = 1.19 (95% CI: 1.12-1.26)
Not recorded as a finding: the intervention held more than the compound
Figure 3 showed that a significant difference was observed in the total effective rate between the folic acid therapy group and the lack folic acid group (95.09% vs.79.06%, pooled RR = 1.19, 95% CI: 1.12–1.26, p < 0.00001).
PMID:39920638 · one of two readings recorded this
neural tube defect (NTD) and spina bifida prevalence per 10,000 births under folic acid fortification/supplementation and arsenic-reduction strategies, decision-analytic model
decreases, reduced to 11.1 and 9.1 per 10,000 births in high and low arsenic exposure groups, respectively
Not recorded as a finding: this platform holds no node for the endpoint
Folic acid fortification reduced the prevalence of NTDs to 11.1 and 9.1 per 10,000 births among high exposure and low exposure groups, respectively.
PMID:40552686 · one of two readings recorded this
neural tube defect (NTD) prevalence per 10,000 births
decreases, 11.1 and 9.1 per 10,000 births (high vs low arsenic-exposure groups) after folic acid fortification
Folic acid fortification reduced the prevalence of NTDs to 11.1 and 9.1 per 10,000 births among high exposure and low exposure groups, respectively.
PMID:40552686 · both readings recorded this
Neural tube defect (NTD) prevalence per 10,000 births under folic acid fortification versus arsenic-reduction strategies, decision-analytic modeling
decreases, 11.1 and 9.1 per 10,000 births (high vs low arsenic-exposure groups)
Not recorded as a finding: this platform holds no node for the endpoint
Folic acid fortification reduced the prevalence of NTDs to 11.1 and 9.1 per 10,000 births among high exposure and low exposure groups, respectively.
PMID:40552686 · one of two readings recorded this
periconceptional folic acid uptake, by parity
decreases, aOR: 0.68; 95% CI 0.63 to 0.74; n=28 studies
For periconceptional use, the odds were 32% lower among multiparous women (aOR: 0.68; 95% CI 0.63 to 0.74; n=28 studies; I2=85.46%).
PMID:42082233 · one of two readings recorded this
Periconceptional folic acid use, multiparous vs primiparous women
decreases, aOR 0.68 (95% CI 0.63 to 0.74)
For periconceptional use, the odds were 32% lower among multiparous women (aOR: 0.68; 95% CI 0.63 to 0.74; n=28 studies; I2=85.46%).
PMID:42082233 · one of two readings recorded this
postconceptional folic acid uptake, by parity
decreases, aOR: 0.79; 95% CI 0.74 to 0.85; n=33 studies
Postconception, the odds were 21% lower among multiparous women (aOR: 0.79; 95% CI 0.74 to 0.85; n=33 studies; I2=85.91%).
PMID:42082233 · one of two readings recorded this
Postconceptional folic acid use, multiparous vs primiparous women
decreases, aOR 0.79 (95% CI 0.74 to 0.85)
Postconception, the odds were 21% lower among multiparous women (aOR: 0.79; 95% CI 0.74 to 0.85; n=33 studies; I2=85.91%).
PMID:42082233 · one of two readings recorded this
Preconceptional folic acid use, multiparous vs primiparous women (including high-risk subgroup)
decreases, aOR 0.71 (95% CI 0.64 to 0.78); high-risk subgroup aOR 0.42 (95% CI 0.27 to 0.64)
For preconceptional use, the odds were 29% lower among multiparous women (adjusted OR (aOR): 0.71; 95% CI 0.64 to 0.78; n=25 studies; I2=88.67%), and 58% lower in multiparous high-risk women (aOR: 0.42, 95% CI 0.27 to 0.64; n=3 studies; I2=27.28%).
PMID:42082233 · one of two readings recorded this
second-trimester folic acid uptake, by parity
no effect, aOR: 0.96; 95% CI 0.87 to 1.05; n=4 studies
By the second trimester, there was no significant difference between the two parity groups (aOR: 0.96; 95% CI 0.87 to 1.05; n=4 studies; I2=0.00%).
PMID:42082233 · one of two readings recorded this
Second-trimester folic acid use, multiparous vs primiparous women
no effect, aOR 0.96 (95% CI 0.87 to 1.05)
By the second trimester, there was no significant difference between the two parity groups (aOR: 0.96; 95% CI 0.87 to 1.05; n=4 studies; I2=0.00%).
PMID:42082233 · one of two readings recorded this
erythrocyte folate concentration
unclear, Hedges' g +0.40 (+0.08 to +0.73) and -0.38 (-0.92 to +0.16); not pooled
The two trials reporting erythrocyte folate were directionally discordant (Hedges' g +0.40; +0.08 to +0.73 and -0.38; -0.92 to +0.16; I2 = 83%) and were not pooled.
PMID:42739064 · both readings recorded this
plasma unmetabolized folic acid (UMFA) concentration
decreases, SMD +0.99 (95% CI +0.20 to +1.79)
5-MTHF substitution reduced plasma UMFA (SMD +0.99; 95% CI +0.20 to +1.79; I2 = 30%; k = 3; GRADE low).
PMID:42739064 · both readings recorded this
Plasma unmetabolized folic acid (UMFA) concentration, erythrocyte folate, and total homocysteine (tHcy) after equimolar substitution of (6S)-5-MTHF for folic acid, meta-analysis SMD/Hedges g
decreases, SMD +0.99 (95% CI +0.20 to +1.79)
Not recorded as a finding: this platform holds no node for the endpoint
5-MTHF substitution reduced plasma UMFA (SMD +0.99; 95% CI +0.20 to +1.79; I2 = 30%; k = 3; GRADE low).
PMID:42739064 · one of two readings recorded this
plasma unmetabolized folic acid (UMFA) concentration, meta-analysis of trials substituting (6S)-5-MTHF for folic acid, SMD
decreases, SMD +0.99; 95% CI +0.20 to +1.79; I2 = 30%; k = 3
Not recorded as a finding: this platform holds no node for the endpoint
5-MTHF substitution reduced plasma UMFA (SMD +0.99; 95% CI +0.20 to +1.79; I2 = 30%; k = 3; GRADE low).
PMID:42739064 · one of two readings recorded this
total homocysteine (tHcy) concentration
no effect
For tHcy, no between-form difference was detected.
PMID:42739064 · both readings recorded this